Auckland, New Zealand–Calocurb announced the publication of a clinical study showing that its bitter hops-based supplement was associated with reductions in body weight, body fat and visceral fat without a loss of muscle mass.
The randomized, double-blind trial evaluated Calocurb over 24 weeks, followed by a three-month participant follow-up. The results were published in the medical journal Obesity Pillars.
Participants who took Calocurb lost an average of 8.4 pounds, or 3.8 kilograms, after six months, compared with 0.9 pounds, or 0.4 kilograms, among those receiving a placebo. Participants were also provided with general healthy diet and exercise guidance.
The Calocurb group lost an average of 9.9 pounds, or 4.5 kilograms, of fat mass, compared with 1.5 pounds, or 0.7 kilograms, in the placebo group. Visceral fat area declined by an average of 5.04 square inches, or 32.5 square centimeters, among Calocurb users, compared with 1.39 square inches, or 9.1 square centimeters, in the placebo group.
Muscle mass increased by an average of 1.9 pounds, or 0.9 kilograms, in the Calocurb group and by 0.44 pounds, or 0.2 kilograms, in the placebo group. The difference in muscle mass between the groups was not statistically significant, according to the company.
The study included 65 participants in the Calocurb group and 63 in the placebo group. Differences between the groups were statistically significant for weight, fat mass, visceral fat and muscle mass-adjusted body weight, but not for the change in muscle mass.
Calocurb contains Amarasate, a patented extract derived from New Zealand bitter hops. The company said the ingredient activates bitter taste receptors in the gastrointestinal tract, stimulating the release of the naturally occurring satiety hormones GLP-1, cholecystokinin and peptide YY.
Unlike prescription GLP-1 receptor agonists, Calocurb is a dietary supplement and does not contain synthetic GLP-1 medication. The company markets it as a nonprescription weight-management product.
“The new clinical data proves not only Calocurb’s contribution to weight loss overall, but also muscle preservation, which is groundbreaking in the crowded space of GLP-1s and other weight reduction options,” said Sarah Kennedy, Founder and CEO of Calocurb. “From our years of research, we knew Calocurb was life-changing for so many, but now we are very excited to present independent clinical data to show its effectiveness across the board to improve body composition, while being 100% natural.”
Calocurb said the latest research represents its fourth human clinical study involving Amarasate. Previous published studies examined the ingredient’s effects on appetite, cravings, caloric intake and the release of satiety hormones.
The supplement is taken twice daily on an empty stomach. Its capsule is designed to release Amarasate in the small intestine, where the extract interacts with bitter taste receptors.
Calocurb is priced at $89.99 for a one-month supply and is marketed in the United States to consumers and health practitioners. (Source: IANS)
